260 related articles for article (PubMed ID: 17235448)
1. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.
Chakraborty A; Murthy NS; Chintamani C; Bhatnagar D; Mohil RS; Sharma PC; Saxena S
J Hum Genet; 2007; 52(2):159-165. PubMed ID: 17235448
[TBL] [Abstract][Full Text] [Related]
2. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
3. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
[TBL] [Abstract][Full Text] [Related]
4. Association of a CYP17 gene polymorphism with development of breast cancer in India.
Surekha D; Sailaja K; Rao DN; Padma T; Raghunadharao D; Vishnupriya S
Asian Pac J Cancer Prev; 2010; 11(6):1653-7. PubMed ID: 21338212
[TBL] [Abstract][Full Text] [Related]
5. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Spurdle AB; Hopper JL; Dite GS; Chen X; Cui J; McCredie MR; Giles GG; Southey MC; Venter DJ; Easton DF; Chenevix-Trench G
J Natl Cancer Inst; 2000 Oct; 92(20):1674-81. PubMed ID: 11036113
[TBL] [Abstract][Full Text] [Related]
6. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Ye Z; Parry JM
Mutagenesis; 2002 Mar; 17(2):119-26. PubMed ID: 11880540
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
Shin MH; Lee KM; Yang JH; Nam SJ; Kim JW; Yoo KY; Park SK; Noh DY; Ahn SH; Kim B; Kang D
Exp Mol Med; 2005 Feb; 37(1):11-7. PubMed ID: 15761247
[TBL] [Abstract][Full Text] [Related]
8. Association between CYP17 gene polymorphism and risk of breast cancer in young women.
Bergman-Jungeström M; Gentile M; Lundin AC; Wingren S
Int J Cancer; 1999 Aug; 84(4):350-3. PubMed ID: 10404084
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in the CYP17 gene and recurrent spontaneous abortions.
Litridis I; Kapnoulas N; Natisvili T; Agiannitopoulos K; Peraki O; Ntostis P; Pantos K; Lamnissou K
Arch Gynecol Obstet; 2011 Feb; 283(2):289-93. PubMed ID: 20069306
[TBL] [Abstract][Full Text] [Related]
10. CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer.
Chacko P; Rajan B; Mathew BS; Joseph T; Pillai MR
Breast Cancer; 2004; 11(4):380-8. PubMed ID: 15604994
[TBL] [Abstract][Full Text] [Related]
11. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ
Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Han DF; Zhou X; Hu MB; Xie W; Mao ZF; Chen DE; Liu F; Zheng F
Chin Med J (Engl); 2005 Sep; 118(18):1507-16. PubMed ID: 16232327
[TBL] [Abstract][Full Text] [Related]
13. Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India.
Dwivedi S; Agrawal S; Singh S; Madeshiya AK; Singh D; Mahdi AA; Chandra A
Asian Pac J Cancer Prev; 2015; 16(13):5557-63. PubMed ID: 26225710
[TBL] [Abstract][Full Text] [Related]
14. [Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women].
Hu MB; Xie W; Xiong B; Han DF; Li Y; Feng MH; Zhou YF
Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Apr; 27(4):351-5. PubMed ID: 16875543
[TBL] [Abstract][Full Text] [Related]
15. The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population.
Tsujino T; Ohara N; Yoshida S; Kennedy S; Takemura N; Deguchi M; Maruo T
Gynecol Endocrinol; 2006 Feb; 22(2):87-91. PubMed ID: 16603433
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.
Zhang L; Gu L; Qian B; Hao X; Zhang W; Wei Q; Chen K
Breast Cancer Res Treat; 2009 Mar; 114(2):327-38. PubMed ID: 18629629
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility.
Huang CS; Chern HD; Chang KJ; Cheng CW; Hsu SM; Shen CY
Cancer Res; 1999 Oct; 59(19):4870-5. PubMed ID: 10519398
[TBL] [Abstract][Full Text] [Related]
19. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer.
Garner EI; Stokes EE; Berkowitz RS; Mok SC; Cramer DW
Cancer Res; 2002 Jun; 62(11):3058-62. PubMed ID: 12036914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
